Adds new sections that set forth conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by state board of pharmacy. The cessation therapies to be covered by all health insurance carriers on or after 1/1/26.
H5854 would authorize licensed pharmacists in Rhode Island to prescribe and dispense FDA-approved tobacco cessation drug therapies to eligible patients under rules adopted by the state Board of Pharmacy, with approval from the director of health and consultation with behavioral health leadership. To qualify, a patient must generally be at least 18 years old (or meet any lower FDA minimum age guidance), agree to participate in a structured cessation program with initial evaluation and follow-up, and be educated about nicotine toxicity and medication risks. Pharmacists would need approved tobacco-cessation training, must refer higher-risk or contraindicated patients to a primary care or other appropriate provider, and must notify the patient’s primary care provider of screening, the prescription record, and follow-up plan within five business days.
The bill also requires broad insurance coverage for tobacco cessation drug therapy beginning January 1, 2026, across group health insurance, nonprofit medical service corporations, and health maintenance organizations. It further requires coverage for pharmacist services within the lawful scope of practice when those services would be covered if performed by a physician, advanced practice nurse, or physician assistant, and bars nonprofit medical service corporations from requiring supervision, signature, or referral as a condition of reimbursement to pharmacists. Health plans must include an adequate number of pharmacists in their provider networks, and out-of-network coverage must be available when the service is not available in-network. The bill also states that tobacco cessation drug therapies would be covered by Medicaid upon approval of a related Section 1115 waiver.
The bill’s impact on state law would be to expand pharmacist prescriptive authority in the pharmacy chapter and to create new insurance mandates in the statutes governing commercial insurers, nonprofit hospital service corporations, nonprofit medical service corporations, and HMOs. It would likely increase access to smoking-cessation medications and pharmacist-led cessation counseling, while also imposing new coverage and network obligations on insurers and potentially increasing reimbursement obligations for pharmacist-delivered services. Because the bill is effective upon passage, the pharmacist-authority provisions would take effect immediately, while the insurance coverage requirements would apply to policies renewed or issued on or after January 1, 2026.
Overall sentiment appears supportive of tobacco cessation access and pharmacist involvement, based on the bill’s structure and sponsor list, but no committee transcripts or recorded votes were provided to show formal debate or opposition. The measure is framed as a public-health and access-to-care bill, with an emphasis on structured counseling, provider coordination, and insurance coverage to reduce barriers to quitting tobacco. Any opposition would likely center on insurer cost, network administration, and the expansion of pharmacist billing and prescribing authority, but those concerns are not documented in the available materials.
Notable points of contention, if raised, would likely involve whether pharmacists should be able to prescribe cessation drugs without physician involvement, how much insurers must pay for pharmacist services, and whether the network adequacy requirement could be burdensome for health plans. Another possible issue is the Medicaid provision, which depends on approval of a Section 1115 waiver and therefore does not guarantee immediate Medicaid coverage. The bill also limits pharmacist prescribing to patients who are willing to participate in follow-up care and requires referral for high-risk or contraindicated cases, which may be intended to address safety concerns.
H5854 would amend Rhode Island’s pharmacy and insurance laws to authorize trained pharmacists to prescribe FDA-approved tobacco cessation therapies and to require health insurance coverage for those therapies and related pharmacist services. It adds new sections to the pharmacy chapter and to the insurance chapters governing commercial insurers, nonprofit hospital service corporations, nonprofit medical service corporations, and HMOs, while also tying Medicaid coverage to a future Section 1115 waiver approval. The bill would expand pharmacist scope of practice, create reimbursement rights for pharmacist-delivered services, and impose network adequacy and coverage mandates on insurers.
The available materials suggest a generally favorable, public-health-oriented bill aimed at improving access to smoking cessation treatment and leveraging pharmacists as accessible providers. There are no committee transcripts or votes showing formal opposition or amendment debate, so the record does not reflect a documented split. Based on the text, the bill appears designed to balance expanded access with safeguards such as training, patient education, referral requirements, and follow-up care.
Potential points of contention include the expansion of pharmacist prescriptive authority, the requirement that insurers reimburse pharmacist services without supervision or referral requirements, and the mandate that plans maintain an adequate number of pharmacists in-network. Insurers may object to added costs and administrative burdens, while some providers may question scope-of-practice expansion or duplication of services. The Medicaid coverage provision is also contingent on federal waiver approval, which could be seen as uncertain or delayed.